779 |
CALCIUM VOLTAGE-GATED CHANNEL SUBUNIT ALPHA1 S |
CACNA1S |
CACNL1A3 |
CCHL1A3 |
Cav1.1 |
HOKPP |
HOKPP1 |
MHS5 |
TTPP1 |
hypoPP |
114208 |
1397 |
ENSG00000081248 |
OTTHUMG00000035784 |
CACN1 |
Q13698 |
CAC1S_HUMAN |
CACH1 |
Voltage-dependent L-type calcium channel subunit alpha-1S |
Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle |
Voltage-gated calcium channel subunit alpha Cav1.1 |
PA85 |
VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL ALPHA-1S SUBUNIT (VOLTAGE- GATED CALCIUM CHANNEL ALPHA SUBUNIT CAV1.1) (CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 3, SKELETAL MUSCLE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q13698] |
Initial Gene Query | Cav1.1 |
Counted Citations from 1950-2000 | 275 |
Human Readable Name | DRUGGABLE GENOME |
Human Readable Name | ION CHANNEL |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR005821 |
Interpro Type | Domain |
Uniprot Status | Swiss-Prot |
Interpro Name | Ion transport domain |
Interpro Short Name | Ion_trans_dom |
Target Class | Transporters |
Target Subclass | TC:1.A.1.11 |
Target Subclass | CalciumChannels |
Target Subclass | Voltage_gated_ion_channels |
Target Subclass | Channels |
Transmembrane Helix Count | 20 |
Target Main Class | Transporters |
Gene Biotype | PROTEIN_CODING |
ION CHANNEL |
DRUGGABLE GENOME |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
Trial Name | Clevelox |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
Trial Name | felodipine ,Plendil |
blocker (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | amlodipine besylate,Norvasc |
Novel drug target | Established target |
Trial Name | Amturnide |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Verapamil,Calan, Covera-HS |
Novel drug target | Established target |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
Direct Interaction | yes |
blocker (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated L-type calcium channel blocker |
blocker (inhibitory) |
Mechanism of Interaction | Voltage-gated calcium channel blocker |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Direct Interaction | yes |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
modulator |
Mechanism of Interaction | Voltage-gated calcium channel modulator |
Direct Interaction | yes |
CACNA1S | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ENSG00000081248 | Ensembl Gene Id |
CACNA1S | Uniprot Gene Name |
CAC1S_HUMAN | Uniprot Id |
Human Readable Name | ION CHANNEL |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR005821 |
ION CHANNEL, DRUGGABLE GENOME |
CACNA1S | Gene Symbol |
Target Class | Transporters |
Target Subclass | TC:1.A.1.11 |
ENSG00000081248 | Ensembl Gene Id |
Q13698 | Uniprot Accession |
CACNA1S | Gene Symbol |
Target Subclass | CalciumChannels |
Target Subclass | Voltage_gated_ion_channels |
Target Subclass | Channels |
779 | Entrez Gene ID |
Initial Gene Query | Cav1.1 |
Counted Citations from 1950-2000 | 275 |
ION CHANNEL |
ENSG00000081248 | Ensembl Gene Id |
CACNA1S | Display Id |
VOLTAGE-DEPENDENT L-TYPE CALCIUM CHANNEL ALPHA-1S SUBUNIT (VOLTAGE- GATED CALCIUM CHANNEL ALPHA SUBUNIT CAV1.1) (CALCIUM CHANNEL, L TYPE, ALPHA-1 POLYPEPTIDE, ISOFORM 3, SKELETAL MUSCLE). [SOURCE:UNIPROT/SWISSPROT;ACC:Q13698] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
PA85 | PharmGKB ID |
ENSG00000081248 | Gene Symbol |
CACNA1S | Ensembl Id |
DRUGGABLE GENOME |
CACN1 | GENE_SYMBOL |
CACNL1A3 | GENE_SYMBOL |
CACNA1S | GENE_SYMBOL |
Voltage-dependent L-type calcium channel subunit alpha-1S | Gene Name |
Q13698 | UniProt ID |
ION CHANNEL |